Consideration of viral resistance for optimization of direct antiviral therapy of hepatitis C virus genotype 1-infected patients

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Dietz, Julia ^a   Susser, Simone ^a   Berkowski, Caterina ^a   Perner, Dany ^a   Zeuzem, Stefan ^a   Sarrazin, Christoph ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ASUNAPREVIR; DACLATASVIR; DASABUVIR; HEPACIVIRIN INHIBITOR; INTERLEUKIN 28B; LEDIPASVIR; NONSTRUCTURAL PROTEIN 5A INHIBITOR; NONSTRUCTURAL PROTEIN 5B INHIBITOR; OMBITASVIR; PARITAPREVIR; SIMEPREVIR; UNCLASSIFIED DRUG; ENZYME INHIBITOR; NS-5 PROTEIN, HEPATITIS C VIRUS; NS3 PROTEIN, HEPATITIS C VIRUS; VIRAL PROTEIN;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENE; GENE MUTATION; GENE SEQUENCE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; IL28B GENE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUTATIONAL ANALYSIS; NONHUMAN; OUTCOME ASSESSMENT; SEQUENCE ANALYSIS; VIRUS LOAD; VIRUS RESISTANCE; AGED; BLOOD; DRUG EFFECTS; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; LEGISLATION AND JURISPRUDENCE; MUTATION; VIROLOGY; YOUNG ADULT;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; MUTATION; SEQUENCE ANALYSIS, RNA; VIRAL NONSTRUCTURAL PROTEINS; YOUNG ADULT;

EID: 84943328674     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0134395     Document Type: Article

References (56)

1. Sarrazin C, Hezode C, Zeuzem S, Pawlotsky JM. Antiviral strategies in hepatitis C virus infection. Journal of hepatology. 2012;56 Suppl 1:S88-100. doi: 10.1016/S0168-8278 (12) 60010-5 PMID: 22300469.
2. Bartenschlager R, Lohmann V, Penin F. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nature reviews Microbiology. 2013;11(7):482-96. doi: 10.1038/nrmicro3046 PMID: 23748342.
3. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384(9956):1756-65. doi: 10.1016/S0140-6736 (14) 61036-9 PMID: 25078309.
4. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvirfor previously treated or untreated chronic HCV infection. The New England journal of medicine. 2014;370(3):211-21. doi: 10.1056/NEJMoa1306218 PMID: 24428467.
5. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. The New England journal of medicine. 2014;370(16):1483-93. doi: 10.1056/NEJMoa1316366 PMID: 24725238.
6. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. The New England journal of medicine. 2014;370(20):1889-98. doi: 10. 1056/NEJMoa1402454 PMID: 24725239.
7. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and sofosbuvirfor8 or 12 weeks for chronic HCV without cirrhosis. The New England journal of medicine. 2014;370(20):1879-88. doi: 10.1056/NE JMoa1402355 PMID: 24720702.
8. Manns M, Pol S, Jacobson IM, Marcellin P, Gordon SC, Peng CY, et al. All-oral daclatasvirplusasunaprevirfor hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet. 2014;384(9954):1597-605. doi: 10.1016/S0140-6736 (14) 61059-XPMID: 25078304.
9. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. The New England journal of medicine. 2014;370(21):1973-82. doi: 10.1056/NEJMoa1402869 PMID: 24725237.
10. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. The New England journal of medicine. 2014;370(17):1594-603. doi: 10.1056/NEJMoa1315722 PMID: 24720703.
11. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourliere M, et al. Retreatmentof HCV with ABT-450/r-ombitasvirand dasabuvir with ribavirin. The New England journal of medicine. 2014;370(17):1604-14. doi: 10.1056/NEJMoa1401561 PMID: 24720679.
12. Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. The New England journal of medicine. 2014;370(21):1983-92. doi: 10.1056/NEJMoa1402338 PMID: 24795200.
13. Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, De Micco M, et al. Sofosbuvir with pegylated interferon alfa-2aand ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase2trial. Lancet. 2013;381(9883):2100-7. doi: 10.1016/S0140-6736 (13) 60247-0 PMID: 23499440.
14. Lawitz E, Gane EJ. Sofosbuvirfor previously untreated chronic hepatitis C infection. The New England journal of medicine. 2013;369(7):678-9. doi: 10.1056/NEJMc1307641 PMID: 23944316.
15. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, et al. Sofosbuvirand ribavirin in HCV genotypes 2 and 3. The New England journal of medicine. 2014;370(21):1993-2001. doi: 10. 1056/NEJMoa1316145 PMID: 24795201.
16. Svarovskaia ES, Dvory-Sobol H, Parkin N, Hebner C, Gontcharova V, Martin R, et al. Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2014;59(12):1666-74. doi: 10.1093/cid/ciu697 PMID: 25266287.
17. Lenz O, Verbinnen T, Lin TI, Vijgen L, Cummings MD, Lindberg J, et al. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrobial agents and chemotherapy. 2010;54(5):1878-87. doi: 10.1128/AAC.01452-09 PMID: 20176898; PubMed Central PMCID: PMC2863659.
18. De Goey DA, Randolph JT, Liu D, Pratt J, Hutchins C, Donner P, et al. Discovery of ABT-267, a pangenotypic inhibitor of HCVNS5A. Journal of medicinal chemistry. 2014;57(5):2047-57. doi: 10.1021/jm401398x PMID: 24400777.
19. Fridell RA, Wang C, Sun JH, O'Boyle DR 2nd, Nower P, Valera L, et al. Genotypicand phenotypicanalysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology. 2011;54(6):1924-35. doi: 10.1002/hep. 24594 PMID: 21809362.
20. Fridell RA, Qiu D, Wang C, Valera L, Gao M. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrobial agents and chemotherapy. 2010;54(9):3641-50. doi: 10.1128/AAC.00556-10 PMID: 20585111; PubMed Central PMCID: PMC2935007.
21. Lawitz EJ, Gruener D, Hill JM, Marbury T, Moorehead L, Mathias A, et al. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. Journal of hepatology. 2012;57(1):24-31. doi: 10.1016/j.jhep. 2011.12.029 PMID: 22314425.
22. Sarrazin C, Dvory-Sobol H, Svarovskaia ES, Doehle B, McCarville JF, Pang PS, et al. Baseline and Post-baseline Resistance Analyses of Phase 2/3 Studies of Ledipasvir/Sofosbuvir ± RBV Hepatology. 2014;60(SupplementS1):1128A.
23. Donaldson EF, Harrington PR, O'Rear JJ, Naeger LK. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology. 2015;61(1):56-65. doi: 10.1002/hep. 27375 PMID: 25123381.
24. Sarrazin C, Schwendy S, Moller B, Dikopoulos N, Buggisch P, Encke J, et al. Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks. Gastroenterology. 2011;141(5):1656-64. doi: 10.1053/j.gastro.2011.07.019 PMID: 21784046.
25. Dietz J, Schelhorn SE, Fitting D, Mihm U, Susser S, Welker MW, et al. Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients. Journal of virology. 2013;87(11):6172-81. doi: 10.1128/JVI.02778-12 PMID: 23536652; PubMed Central PMCID: PMC3648094.
26. Lim SR, Qin X, Susser S, Nicholas JB, Lange C, Herrmann E, et al. Virologic escape during danoprevir (ITMN-191/RG7227) monotherapy is hepatitis C virus subtype dependent and associated with R155K substitution. Antimicrobial agents and chemotherapy. 2012;56(1):271-9. doi: 10.1128/AAC.05636-11 PMID: 22064535; PubMed Central PMCID: PMC3256012.
27. Bartels DJ, Sullivan JC, Zhang EZ, Tigges AM, Dorrian JL, De Meyer S, et al. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. Journal of virology. 2013;87(3):1544-53. doi: 10.1128/JVI.02294-12 PMID: 23152524; PubMed Central PMCID: PMC3554180.
28. Hall TA. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symposium. 1999;41:95-8.
29. Kolykhalov AA, Agapov EV, Blight KJ, Mihalik K, Feinstone SM, Rice CM. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science. 1997;277(5325):570-4. PMID: 9228008.
30. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science. 1999;285(5424):110-3. PMID: 10390360.
31. Lenz O, Verbinnen T, Fevery B, Tambuyzer L, Vijgen L, Peeters M, et al. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies. Journal of hepatology. 2014; Epub. doi: 10.1016/j.jhep. 2014.11.032 PMID: 25445400.
32. McPhee F, Friborg J, Levine S, Chen C, Falk P, Yu F, et al. Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir. Antimicrobial agents and chemotherapy. 2012;56(7):3670-81. doi: 10.1128/AAC.00308-12 PMID: 22508297; PubMed Central PMCID: PMC3393445.
33. Krishnan P, Tripathi R, Irvin M, Beyer J, Reisch T, Schnell G, et al. Lack of impact of baseline resistance-associated variants (RAVs) on treatment outcome in the aviator study with ABT-450/r, ABT-333 and ABT-267, +/- ribavirin. Journal of hepatology. 2014;60(1):S498.
34. Pilot-Matias T, Tripathi R, Cohen D, Gaultier I, Dekhtyar T, Lu L, et al. In Vitro and In Vivo Antiviral Activity and Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor ABT-450. Antimicrobial agents and chemotherapy. 2015;59(2):988-97. doi: 10.1128/AAC.04227-14 PMID: 25451053.
35. Kati W, Koev G, Irvin M, Beyer J, Liu Y, Krishnan P, et al. In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor. Antimicrobial agents and chemotherapy. 2015;59(3):1505-11. doi: 10.1128/AAC04619-14 PMID: 25534735; PubMed Central PMCID: PMC4325770.
36. Krishnan P, Beyer J, Mistry N, Koev G, Reisch T, De Goey D, et al. In Vitro and In Vivo Antiviral Activity and Resistance Profile of Ombitasvir, an Inhibitor of Hepatitis C Virus NS5A. Antimicrobial agents and chemotherapy. 2015;59(2):979-87. doi: 10.1128/AAC.04226-14 PMID: 25451055.
37. Svarovskaia ES, Dvory-Sobol H, Doehle B, Gane EJ, Jacobson IM, Nelson DR, et al. L159Fand V321A SofosbuvirTreatment-Emergent HCV NS5B Substitutions. Hepatology. 2014;60(S1):218A.
38. Tong X, Le Pogam S, Li L, Haines K, Piso K, Baronas V, et al. In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir. The Journal of infectious diseases. 2014;209(5):668-75. doi: 10.1093/infdis/jit562 PMID: 24154738.
39. De Luca A, Bianco C, Rossetti B. Treatment of HCV infection with the novel NS3/4A protease inhibitors. Current opinion in pharmacology. 2014;18C:9-17. doi: 10.1016/j.coph.2014.07.016 PMID: 25117198.
40. Gaudieri S, Rauch A, Pfafferott K, Barnes E, Cheng W, McCaughan G, et al. Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology. 2009;49(4):1069-82. doi: 10.1002/hep. 22773 PMID: 19263475.
41. Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young SK, et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology. 2008;48(6):1769-78. doi: 10.1002/hep. 22549 PMID: 19026009; PubMed Central PMCID: PMC2645896.
42. Vermehren J, Sarrazin C. The role of resistance in HCV treatment. Best practice & research Clinical gastroenterology. 2012;26(4):487-503. doi: 10.1016/j.bpg.2012.09.011 PMID: 23199507.
43. Poordad F, Lawitz E, Kowdley KV, Cohen DE, Podsadecki T, Siggelkow S, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. The New England journal of medicine. 2013;368(1):45-53. doi: 10.1056/NEJMoa1208809 PMID: 23281975.
44. Lok AS, Gardiner DF, Hezode C, Lawitz EJ, Bourliere M, Everson GT, et al. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. Journal of hepatology. 2014;60(3):490-9. doi: 10.1016/j.jhep. 2013.10.019 PMID: 24444658.
45. Schneider MD, Sarrazin C. Antiviral therapy of hepatitis C in 2014: do we need resistance testing? Antiviral research. 2014;105:64-71. doi: 10.1016/j.antiviral.2014.02.011 PMID: 24583028.
46. Sarrazin C, Dvory-Sobol H, Svarovskaia ES, Doehle B, Martin R, Zeuzem S, et al. The prevalence and the effect of HCV NS5A resistance associated variants in subjects with compensated cirrhosis treated with ledipasvir/sofosbuvvir+/-RBV. Journal of hepatology. 2015;62(1):S620.
47. Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, et al. Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or posttransplant recurrence: phase 3 Ally-1 study. Journal of hepatology. 2015;62(1):S261.
48. Kwo P, Gitlin N, Nahass R, Bernstein D, Rojter S, Schiff E, et al. A phase 3, randomised, open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naive and-experienced patients with chronic HCV genotyope 1 infection without cirrhosis: Optimist-1. Journal of hepatology. 2015;62(1):S270.
49. Sarrazin C, Lathouwers E, Peeters M, Daems B, Buelens A, Witek J, et al. Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region. Antiviral research. 2015;116C:10-6. doi: 10.1016/j.antiviral.2015.01.003 PMID: 25614456.
50. McPhee F, Hernandez D, Yu F, Ueland J, Monikowski A, Carifa A, et al. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir. Hepatology. 2013;58(3):902-11. doi: 10.1002/hep. 26388 PMID: 23504694.
51. Lawitz E, Matusow G, DeJesus E, Yoshida E, Felizarta F, Ghalib R, et al. A phase-3 open-label, singlearm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naive or-experienced patients with chronic HCV genotype 1 infection and cirrhosis: Optimist-2. Journal of hepatology. 2015;62(1):S264.
52. Suzuki Y, Ikeda K, Suzuki F, Toyota J, Karino Y, Chayama K, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. Journal of hepatology. 2013;58(4):655-62. doi: 10.1016/j.jhep. 2012.09.037 PMID: 23183526.
53. Suzuki F, Sezaki H, Akuta N, Suzuki Y, Seko Y, Kawamura Y, et al. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology. 2012;54(4):352-4. doi: 10.1016/j.jcv. 2012.04.024 PMID: 22658798.
54. Wyles DL, Ruane P, Sulkowski MS, Dieterich D, Luetkemeyer AF, Morgan TR, et al. Daclatasvir plus sofosbuvir for treatment of HCV genotypes 1-4 in HIV-HCVcoinfection: The Ally-2 study. Journal of hepatology. 2015;62(1):S263.
55. Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61(4):1127-35. doi: 10.1002/hep. 27726 PMID: 25614962; PubMed Central PMCID: PMC4409820.
56. Krishnan P, Tripathi R, Schnell G, Reisch T, Beyer J, Irvin M, et al. Pooled analysis of resistance in patients treated with ombitasvir/ABT-450/r and dasabuvir with or without ribavirin in Phase 2 and Phase 3 clinical trials. Hepatology. 2014;60(S1):1134A-5A.